Suven Life Sciences Limited

This study tested a new drug, ropanicant, in 41 adults with moderate to severe major depression. The main goal was to see if the drug is safe and to measure any side effects. Researchers also looked at whether depression symptoms improved using a standard rating scale.

This study tested a new drug called ropanicant in 214 adults with major depression. Participants received one of two doses or a placebo for 6 weeks. The goal was to see if the drug reduces depression symptoms better than a placebo. The trial is now complete, and results will show…

This early-stage study tested a new drug called SUVN-I6107 in 64 healthy adults to see if it is safe and how the body processes it. Participants took single or multiple doses by mouth, and researchers monitored side effects, vital signs, and brain activity. The goal was to gather…